Tender results December 2023
Pharmac has resolved to decline tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender, dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical name |
Line item |
|---|---|
|
Morphine |
Tab immediate-release 10 mg |
|
Morphine |
Tab immediate-release 20 mg |
|
Oxycodone hydrochloride |
Cap 5 mg |
|
Oxycodone hydrochloride |
Cap 10 mg |
|
Oxycodone hydrochloride |
Cap 20 mg |
|
Oxycodone hydrochloride |
Oral liq 1 mg per ml |
Pharmac has been unable to resolve these tenders through the 2023/24 Invitation to Tender. Due to this, Pharmac has prioritised the decline of these tenders so it can continue investigating alternative supply options for these markets. Please follow our website for further updates on the supply of these products.
For products included in the 2021/22, 2022/23 and 2023/2024 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 660 050.